November 18, 2016

ASTRO Releases New APBI Guidelines: What Clinicians Need to Know (Video)

Key takeaways of the evidence-based consensus statement

Accelerated partial breast irradiation (APBI) allows appropriately selected patients with early-stage breast cancer to complete adjuvant radiation in one week or less following breast conserving surgery. To date, multiple randomized trials have demonstrated no difference in rates of recurrence or survival with APBI delivered using brachytherapy or external beam radiation techniques.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In this video, Cleveland Clinic radiation oncologist Chirag Shah, MD, discusses the American Society of Radiation Oncology’s newly released updated guidelines for the off-protocol use of APBI. Most significantly, the guidelines lower the age cut-off from age 60 and older to age 50 and older, as well as include patients with ductal carcinoma in citu (low/intermediate grade, < 2.5 cm, negative surgical margins).

Dr. Shah also explains that suitable candidates for APBI include those 50 years or older with tumors < 3.0 cm, with negative margins, and that are estrogen receptor positive. With respect to intraoperative radiation (IORT), the new guidelines recommend counseling that IORT is associated with higher rates of local recurrence and that electron IORT be limited to only suitable APBI patients, while low-energy X-ray IORT should be limited to prospective registries or clinical trials.

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

October 18, 2023
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650&#215;450 Dr Yu
October 9, 2023
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650&#215;450 scan for triple-negative breast cancer case study
September 19, 2023
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650&#215;450 eye toxicities in cancer treatment
September 7, 2023
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

August 31, 2023
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust